KRYSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Krystal Biotech, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$320.25+3.67 (+1.16%)
Close on Oct 19, 2026
- Market cap
- $9.82B
- P/E (TTM)
- 40.1
- Dividend yield
- –
Krystal Biotech, Inc. revenue by segment
By business segment
By product or service
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $91.63M | $87.49M | – | – | $96.04M | $88.18M | – | – | – | – | 76.9% | -4.6% |
| Europe | $19.28M | $20.68M | – | – | $0 | $0 | – | – | – | – | 16.2% | – |
| Japan | $8.31M | $8.19M | – | – | $0 | $0 | – | – | – | – | 7.0% | – |
From the segment and revenue-disaggregation notes of Krystal Biotech's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.